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Here, we provide an overview of the concept of a lactate-protected hypoglycemia
(“LPH”), originally proposed as lowering glucose while simultaneously increasing lactate
concentration as a method by which tumors might be targeted. Central to this
hypothesis is that lactate can act as a critical salvage fuel for the central nervous
system, allowing for wide perturbations in whole body and central nervous system
glucose concentrations. Further, many tumors exhibit “the Warburg” effect, consuming
glucose and producing and exporting lactate despite adequate oxygenation. While
some recent data have provided evidence for a “reverse-Warburg,” where some tumors
may preferentially consume lactate, many of these experimental methods rely on a
significant elevation in lactate in the tumor microenvironment. To date it remains unclear
how various tumors behave in vivo, and how they might respond to perturbations in
lactate and glucose concentrations or transport inhibition. By exploiting and targeting
lactate transport and metabolism in tumors (with a combination of changes in lactate
and glucose concentrations, transport inhibitors, etc.), we can begin developing novel
methods for targeting otherwise difficult to treat pathologies in the brain and spinal cord.
Here we discuss evidence both experimental and observational, and provide direction
for next steps in developing therapies based on these concepts.
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Beginning with its discovery in 1780, lactate was once thought of as a dead-end waste product,
formed in times of poor perfusion or hypoxia (Ferguson et al., 2018). This view dominated for
much of the ensuing 200 years, until the 1980’s, when, on the basis of studies on both animals
and humans, George Brooks proposed the cell-to-cell lactate shuttle hypothesis (Brooks, 2002,
2018; Gladden, 2004). Those studies ranged from isolated organs to intact humans, employing
techniques such as muscle biopsies, arteriovenous differences combined with tissue blood flow, and
radioactive tracer methods. Evidence supporting this hypothesis has continued to accumulate and
it is now universally accepted as biological theory (Brooks, 2002, 2018; Gladden, 2004; Ferguson
et al., 2018). The cell-cell shuttle is the mechanism by which whole body lactate metabolism is
coordinated. Rather than a waste product formed during hypoxia, lactate is a dynamic intermediate
that is constantly produced and consumed, exported from some tissues and taken up by others to
be oxidized as fuel or stored as glycogen. While oxygen is required for oxidative phosphorylation,
the pO2 experienced in vivo is almost never low enough to limit cytochrome turnover significantly
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blood-brain barrier itself (Pardridge, 1986), is clearly a major
player in the central nervous system in both health and disease
(Brooks, 2018). To date, data continue to accrue in favor of
lactate as a primary metabolite at the center of metabolism
(Hensley et al., 2016; Faubert et al., 2017; Harjes, 2017; Hui et al.,
2017; Brooks, 2018).
Recently, studies on lactate in the tumor microenvironment
have shed considerable light on lactate’s role in metabolism.
Studies on tumor metabolism have dated back to the 1920’s, when
it was reported that tumors in solution acidified the surrounding
environment and experienced an elevated [lactate] in response to
the addition of glucose (Warburg and Minami, 1923; Ferguson
et al., 2018). The Cori and Cori (1925) reported that venous
blood draining a sarcoma-bearing wing was higher in [lactate]
[and lower in (glucose)] than the contralateral wing, while
Otto Warburg observed that lactate production in rat hepatoma
slices was on the order of ∼70 times that seen in normal
tissue, regardless of O2 availability (Otto, 2016). When Warburg
examined the inflow and outflow of tumors in rats, he found
that the artery feeding the tumor always had a higher [glucose]
and lower [lactate] then the vein draining it (Warburg et al.,
1927). This glucose-avid, lactate-producing phenotype has since
been dubbed the “Warburg effect,” and has been demonstrated
across a wide variety of tumor types, forming the basis of the
extra-ordinary ability of the FDG-PET scan to detect most types
of solid cancers.
With the introduction of the cell-cell lactate shuttle in the
1980s, a new understanding of lactate metabolism emerged.
However, it was not until 2008, with the publication suggesting
there was lactate shuttling within tumors from Sonveaux et al.
(2008), that lactate made its appearance on center stage in
oncology. In his commentary summarizing this work, Gregg
Semenza, himself the discoverer of HIF-1α and Nobel Laureate,
paid homage to the work done in muscle physiology on lactate
shuttling, “Was there any precedent that should have alerted
us to the existence of this symbiotic relationship between
aerobic and hypoxic cancer cells? Of course; the well-known
recycling of lactate in exercising muscle (Semenza, 2008).”
Sonveaux et al. (2008) demonstrated that some tumor cells seem
better suited for oxidative metabolism and the use of lactate
as a fuel than are others. Studying human cervix squamous
carcinoma cells (SiHa) and human colorectal adenocarcinoma
cells (WiDr), they demonstrated that SiHa cells were oxidative
and would readily use lactate as fuel, whereas WiDr cells
were more glycolytic, consuming glucose and producing lactate
in a Warburg-type manner. MCT1 inhibition (or silencing)
blocked lactate-fueled respiration of the SiHa cells. These same
researchers slowed tumor growth in Lewis lung carcinoma
(LLc) and WiDr mouse models by injecting the MCT inhibitor
a-cyano-4-hydroxycinnamate (CHC). However, this treatment
was unsuccessful in slowing growth in transplantable liver tumor
cells (TLT), which have very little expression of MCT1. These
authors posited that cells at the hypoxic core of a tumor may
produce lactate by necessity, while more peripheral cells with
ample O2 supply could then take up that lactate and use it as a
fuel. However, while both WiDr and SiHa cells used lactate to
some degree when no glucose was available, no definitive data

below its maximum rate (Richardson et al., 1995; Heino et al.,
1997). Contrary to the original teaching and dogma, lactate is
being produced, circulated, and consumed in a near-independent
manner from oxygen.
We now know that skeletal muscle serves as a fuel reservoir,
with glycogen stores that can be broken down to lactate in
response to catecholamines binding β-adrenergic receptors on
the muscle cell membrane (Daniel et al., 1978; Gore et al., 1991;
Garcia-Alvarez et al., 2014; Goodwin et al., 2019). Lactate can
then passively diffuse down its concentration gradient out of
the cell and into other tissues via monocarboxylate transporters
(MCTs), where it can be used as a fuel (Halestrap and Price,
1999). In times of whole animal stress (i.e., fight-or-flight, trauma,
burns, traumatic brain injury), this mechanism allows rapid
mobilization of fuel at little cost (Gore et al., 1991; GarciaAlvarez et al., 2014; Brooks and Martin, 2015). The enzyme lactate
dehydrogenase (LDH) catalyzes the near-equilibrium pyruvate
to lactate reaction. Lactate dehydrogenase is present at a higher
activity than any of the other enzymes in either glycolysis or
oxidative metabolism. As a result, lactate is constantly being
formed and consumed almost instantaneously (Goodwin et al.,
2015; Rogatzki et al., 2015; Bak and Schousboe, 2017). With
its large reservoir in the form of glycogen, movement down
concentration gradients without the need for energy input, and
rapid conversion to pyruvate once inside a cell, lactate is an
excellent fuel source for most tissues of the body; the central
nervous system is no exception (Gladden, 2000; Brooks and
Martin, 2015; Brooks, 2018; Ferguson et al., 2018).
Pellerin and Magistretti (1994) introduced the original
astrocyte-neuron lactate shuttle (ANLS), proposing that
astrocytes take up glucose and then release lactate for use by
nearby neurons. In this model MCT1s and MCT4s have been
proposed as responsible for exporting lactate from astrocytes,
while MCT2s have been proposed as importing lactate into
neurons (Pellerin and Magistretti, 2012). While MCTs are
bidirectional in nature, studies on their distribution have proven
their expression to be tissue-specific: MCT1s are expressed in
astrocytes, oligodendrocytes, endothelial cells, and many other
tissues throughout the body, MCT4s are expressed in astrocytes
but not neurons (as well as in muscle cells and a few other places
throughout the body), and MCT2s are found predominantly in
neurons. While a comprehensive review of MCTs is beyond the
scope of this paper, it should be noted that the affinity of each
MCT for lactate varies markedly and likely contributes to their
tissue-specific expression. For example, MCT2 has a high affinity
for lactate (Km ∼ 0.7 mM) and its expression has proven to be
inducible, such that a rapid increase in expression can allow
for rapid changes in lactate transport (Pellerin and Magistretti,
2012). MCT1 and MCT4, in contrast, have a lower affinity for
lactate (Kms of ∼3.5 and 34 mM, respectively). While affinity for
lactate and thus responsiveness varies, care must be taken not to
confuse this with directionality, which is ultimately determined
by lactate concentration. Depending on the metabolic state, for
example, MCT1s may function as lactate importers or exporters.
While the ANLS concept and the experiments supporting it
have been debated, the importance of lactate within the CNS is
clear. Lactate, whether formed by astrocytes, or by crossing the
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First, lactate’s role has expanded beyond that of a metabolite –
it is now known to function as a signaling molecule as well
(Errea et al., 2016; Brown et al., 2020). Although beyond the
scope of this review, one of the most intriguing roles lactate
plays is as the primary ligand for the hydroxycarboxylic acid
receptor 1 (HCAR1), also known as GPR81. This G-protein
coupled receptor appears to promote tumorigenesis in both an
autocrine and paracrine fashion (Brown et al., 2020; Hu et al.,
2020). LPH as a strategy to target tumors becomes increasingly
more challenging if lactate itself is a ligand that binds to stimulate
oncogenic pathways. For example, in the case of GPR81,
lactate binding and the resultant tumorigenesis is independent
of transport via MCTs. Currently work is ongoing in this
area. Second, recent studies demonstrating lactate-consuming
behavior of tumor cells seems to conflict with previous data. For
example, how do we reconcile recent studies that demonstrate a
reverse-Warburg phenotype in tumors that clinically are glucoseconsuming, PET-positive, Warburg-type cells? And where does
this leave our LPH hypothesis, whereby inducing a whole-animal
hypoglycemia may starve tumor cells, while providing lactate
in the form of hyperlactatemia may act as a salvage fuel for
non-tumor tissues (Figure 1)?

demonstrated that cancer cells of the same type might shuttle
lactate within one tumor microenvironment. Further, the lack
of control cells in these studies makes comparison to “normal”
metabolism difficult. Unfortunately, how to use these and other
data to progress to the next step in a translational model is
unclear; the experimental conditions are too far removed from
in vivo conditions (Muir et al., 2018). For example, human cervix
squamous carcinoma, characterized by Sonveaux et al. (2008) as
oxidative and a “lactate consumer” (or “Reverse Warburg”) is
a glucose-consuming, PET-positive tumor in vivo (i.e., lactateproducing or “Warburg”) (Walenta et al., 2000).
Using a “lactate-protected hypoglycemia (LPH)” as a strategy
to target glucose-avid, lactate-producing tumors was first
described in 2008 by Nijsten and Van Dam (2009). In this
proposal the authors posit that the Warburg behavior of tumors
might be targeted by inducing a deep hypoglycemia while
providing lactate as a salvage fuel for non-tumorous tissues. Since
this was proposed, however, two areas of research have suggested
this may be quite difficult to implement as a therapeutic treatment
on its own: (1) lactate’s emerging role as a signaling molecule
in tumorigeness and (2) tumors that appear to demonstrate a
“reverse Warburg” phenotype, consuming lactate.

FIGURE 1 | During normal conditions (A,B), circulating glucose is taken up by normal (A) and tumor (B) cells, with tumor cells being more glucose-avid (represented
by the thicker black line denoting glucose from blood to the cell) and exporting more lactate (represented by the thicker black line denoting lactate from cell to blood).
Note the relative increase in ATP production from glycolysis in tumor cells and the concomitant slightly less ATP from oxidative phosphorylation (represented by size
of ATP in box). During lactate-protected hypoglycemia (LPH) (C,D), circulating glucose is dramatically lowered and glucose uptake into both normal (C) and tumor
(D) cells is impaired (dotted lines from blood to cell glucose). At the same time hyperlactatemia serves as a salvage fuel for normal cells, while tumor cells,
accustomed to lactate export, have a less robust ability to import and use lactate. Note decreased ATP production via glycolysis from both cells with an increase in
oxidative phosphorylation ATP production from lactate import in normal cells and an overall impaired ATP production from tumor cells. Note that LPH alone, while
elegant in its use of lactate as a salvage fuel for the CNS, may prove to be problematic as tumor cells may adjust and begin taking up lactate when (1) glucose
becomes limiting, and/or (2) lactate becomes abundant. Further, MCT expression profiles in tumors often differ when compared to non-tumor tissues, suggesting
that the use of LPH in conjunction with selective targeting of tumor MCTs may be more effective than LPH alone.
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(1) lactate transport into tumor cells is specifically inhibited, or
(2) tumor-perfusing blood lactate concentrations are not high
enough to induce lactate uptake by a tumor cell that otherwise
would prefer lactate output. The efficacy of LPH in targeting
tumor cell metabolism, alone or as an adjuvant, is yet to be
determined in humans.

Many recent studies that suggest lactate is a preferred fuel
source of tumor cells fail to recognize the importance of
the extracellular lactate concentration as a determinant of the
direction of lactate diffusion (i.e., into or out of the cell).
MCTs are bidirectional transporters and can function both to
import and export lactate, albeit with a differing K m and thus
differing responsiveness to concentration changes (Halestrap
and Price, 1999; Ferguson et al., 2018; Glancy et al., 2020).
Bonuccelli et al. (2014) demonstrated that osteosarcoma cells
consume lactate, whereas Sonveaux et al. (2008) posited the
same with cervical cancer cells, and still others have made
similar claims with a variety of other cancer cells and models
(Sanchez et al., 2013; Pértega-Gomes and Baltazar, 2014;
Faubert et al., 2017; Harjes, 2017). However, these experiments
typically involve use of supraphysiologic concentrations of
lactate (e.g., ∼10 mM). In mice, an alveolar soft parts sarcoma
(ASPS) model demonstrated that lactate drove tumorigenesis,
acting as a fuel and driving HIF1α (Goodwin et al., 2014).
Tumors in this model, as noted, only formed in areas of high
lactate concentration (all formed in the cranial vault, where
lactate concentration was on the order of 6–9 mM). Work
by Pagliassotti and Donovan (1990) in muscle demonstrated
long ago that even the most glycolytic, lactate-producing
muscles will revert to taking up lactate as the systemic lactate
perfusing them rises above 4 mM. In the ASPS mouse, a high
lactate concentration allowed for tumor initiation and growth;
augmentation with daily lactate injections further increased
vascularity and markers of proliferation (Ki67) within these
tumors (Goodwin et al., 2014). All of these environments (ASPS
mice and isolated cells) contain a higher extracellular lactate
concentration than what is found in the human extracellular
milieu of the CNS (∼2.5 mM) (Turner and Adamson, 2011).
This small factor is critical when determining if and when tumors
produce or consume lactate. In high-lactate environments,
almost all tissues will take up lactate. The results – that
isolated cells in 10 mM lactate consume lactate, or ASPS
mouse tumor cells in 6–9 mM take up lactate – should
not surprise us.
Overall, it is likely that many tumor cells are glucose-avid,
PET-positive Warburg cells. However, when glucose becomes
limiting or lactate becomes abundant, both the CNS and many
tumors can likely readily use lactate as a fuel. LPH, while elegant
in its use of lactate as a salvage fuel for the CNS, may prove
to be problematic as tumor cells adjust and begin taking up
lactate when (1) glucose becomes limiting, and/or (2) lactate
becomes abundant. Further, lactate itself may act as a signaling
molecule, further impeding efforts to use it as a salvage fuel.
Given this, the use of LPH in conjunction with selective targeting
of tumor cell lactate transport (MCTs) seems more likely to be
efficacious than LPH alone.
To summarize, lactate is a valuable metabolite that is
constantly shuttling between tissues, coordinating whole-body
and CNS metabolism. While isolated studies have suggested some
cancer cells may consume lactate rather than produce it, this is
likely due in large part to the experimental designs used, where
lactate is ∼10 times normal. In attempts to use LPH as a strategy
to target tumors in vivo, care must be taken to ensure either
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DATA SUPPORTING LPH IN VITRO
Both human case reports and animal studies provide indirect
evidence that lactate can serve as a salvage fuel during times
of severe hypoglycemia (Gladden et al., 2011; Oldenbeuving
et al., 2014; Ferguson et al., 2018; Goodwin et al., 2019; Glancy
et al., 2020). More direct evidence is littered throughout the
literature and much of the detail is beyond the scope of
this brief commentary, as it is now well-accepted within the
framework of the cell-cell lactate shuttle and the astrocyte-neuron
lactate shuttle (Brooks, 2018; Glancy et al., 2020). In Avital
Schurr’s seminal work in Science in 1988 (Schurr et al., 1988),
rat hippocampus slices were isolated and membrane potentials
measured. When glucose was removed, tissue slices rapidly lost
membrane potential; then when lactate was added, the membrane
potential quickly recovered. This concept has been repeated in
a variety of cellular experiments, demonstrating lactate’s ability
to diffuse into cells via MCTs, where it can then be utilized as a
fuel (Brooks, 2002, 2018). Now, advances like the Seahorse assay
purport to quantify cell metabolism via extracellular acidification
rate (ECAR) as well as oxygen consumption rate (OCR) (van
der Windt et al., 2017). While limits to the Seahorse assay (and
others like it) exist, when used in conjunction with studies
examining MCT expression, lactate and glucose concentrations,
and whole genome transcriptome changes, any given tissue’s
reliance on lactate as a fuel can be readily quantified and
compared to other tissues.

DATA FOR LPH IN VIVO
Nijsten and van Dam (2009) proposed the framework for LPH
based on a variety of studies both in vitro and in vivo; the data
support lactate as a potent fuel source for the CNS. Oldenbeuving
et al. (2014) reported the case of a patient who presented to
the Emergency Department ambulatory and conversant despite
a glucose level of only 0.7 mM (∼12.6 mg/dL). Normally this
level of hypoglycemia is associated with coma or even death. In
this case report the patient was in hepatic failure and lacked the
ability to synthesize new glucose at the liver via gluconeogenesis.
However, his arterial lactate was 25 mM. Given what is known
about the central nervous system’s reliance on lactate, this case
report provides circumstantial evidence for lactate acting as a
CNS salvage fuel during hypoglycemia (for full discussion see
Faubert et al., 2017). Other indirect evidence for lactate as a
salvage fuel exists, including neonatal lactate concentrations on
the order of 6–9 mM before the liver is mature enough for
gluconeogenesis (Medina, 1985; Ohki et al., 1999).
In order to better understand lactate’s ability to serve as a
salvage fuel during extreme hypoglycemia, we performed a series
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of trials in anesthetized dogs in which severe hypoglycemia
was induced during hyperlactatemia (Ferguson et al., 2018). In
these experiments animals were infused with sodium lactate
for up to 10 h while acid base balance was controlled.
The primary endpoint was brain electrical activity (EEG).
After induction of hyperlactatemia, hypoglycemia was induced
through a combination of insulin, -β-blockade, biguanides, and
ethanol. During trials of deep hypoglycemia without lactate
infusion, brain death ensued within ≈30 min. When lactate was
present as a salvage fuel (∼10 mM), animals lived for up to
∼6–8 h (Figure 2).
While early data for LPH as a therapy are promising,
challenges remain. Many tissues of the central nervous system
are capable of utilizing lactate, making LPH attractive. For
example, in humans the spinal cord glial cells rely heavily on
lactate. Oligodendrocytes, for example, rely on large amounts
of lactate for myelination, as it serves as the main precursor
for lipogenesis. Sánchez-Abarca et al. (2001) demonstrated that
oligodendrocytes used ∼5x as much lactate as either neurons
or astrocytes. This reliance on lactate is critical in the human
spinal cord, where the glia-neuron ratio is markedly higher

than other mammalian spinal cords (∼6–7 vs. ∼1–2), and
even higher than that of the cerebral cortex (Bahney and
von Bartheld, 2019). Supporting the hypothesis that lactate is
critical to spinal cord function, patients with amyotrophic lateral
sclerosis (ALS) express lower amounts of MCT1, and non-ALS
patients exhibit ALS-type symptoms when MCT1 is inhibited,
both presumably due to impairment of oligodendrocyte lactate
transport (Rinholm, 2011). Mouse ALS models further support
this mechanism, as the ALS mouse is also deficient in MCT1
(Rinholm, 2011).
The “milieu” of the central nervous system has long been
known to be a “lactate rich” environment, typically with an
extracellular space [lactate] of around 2.5 mM (Turner and
Adamson, 2011). In work on a transgenic mouse model of
ASPS, the cranial vault (not in any particular type of tissue,
but rather in the space of the that environment) proved to be
where tumors formed preferentially; administration of exogenous
lactate increased this tumorigenesis (Goodwin et al., 2014).
Cranial vault lactate concentration proved to be on the order of
≈6–8 mM and increased with daily lactate injections. The human
cranial vault, however, has a much lower lactate concentration,
and presumably provides a different tumor microenvironment
than the mouse (Turner and Adamson, 2011; Goodwin et al.,
2014). Does this difference in lactate concentration influence fuel
choice by cells? According to work by Sonveaux et al. (2008) and
others, some tumor cells may prefer lactate as a fuel, potentially
rendering LPH relatively useless. However, as noted earlier, the
context in which many of these experiments were performed
must be noted, as many used lactate concentrations that were
≈10x the normal concentration. Again, this concentration is
known to induce lactate uptake into almost any cell it bathes
(Pagliassotti and Donovan, 1990).

CONCLUSION AND FUTURE
DIRECTIONS
Utilizing an approach that lowers glucose while providing lactate
(i.e., “LPH”) is a tantalizing and novel way of targeting tumors,
given the reliance of many host tissues on lactate, and the
preference of many tumors to produce rather than consume
lactate. Many tumors likely differ in not only their preference for
lactate, but also in their MCT expression profile in comparison
to the non-tumor tissue around it. This may potentially permit
selective inhibition of particular MCTs in an effort to target tumor
cells. For example, if a tumor presents in the CNS that expresses
MCT4 but little MCT1, inhibition of MCT4 may selectively target
tumor cells while allowing non-tumor tissue to continue its use of
lactate as a fuel. Because MCT1 and 2 are expressed throughout
the CNS as noted (e.g., MCT2s in neurons and MCT1s along with
MCT4s in astrocytes), inhibition of MCT4 would theoretically
stop a tumor’s sole mechanism for transporting lactate, while
CNS tissues would have another MCT subtype that could increase
its activity accordingly (e.g., MCT1s in astrocytes). In this
scenario, MCT4 blockade with or without LPH could prove
efficacious in targeting tumors. Currently more experimentation
is needed, as (1) tumor cells can exhibit a significant

FIGURE 2 | In anesthetized canines, hypoglycemia without a salvage fuel is
not well tolerated (A); isoelectric brain death is seen around 30 min after
hypoglycemia. When lactate is provided as a salvage fuel (B), brain activity is
maintained for 6–8 h after hypoglycemia induction. Note the difference in
scale of the X and Y axes of the two figures. Used with permission from
Ferguson et al. (2018).
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amount of metabolic plasticity (Ždralevic et al., 2017), and (2)
there is potential for dramatic deleterious side effects in the
CNS when inhibiting lactate transport (Rinholm, 2011). Studies
are currently ongoing in our lab examining this and other
combinations in various tumor lines.
In conclusion, lactate is the “central” molecule in both
whole body and central nervous system metabolism. Many
neural tissues utilize lactate, highlighted by shuttles within the
brain, but also by the critical role lactate plays as a lipogenic
precursor in the human spinal cord. Targeting lactate metabolism
in different diseases is a promising possibility in the near
future, but care must be taken to understand the normal
physiology of lactate in the CNS. Future work will determine the
efficacy of targeting central nervous system tumors utilizing an
LPH-based approach.
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